Senzar Asset Management LLC Trimmed Its Halozyme Therapeutics INC (HALO) Stake by $4.37 Million

Halozyme Therapeutics, Inc. (NASDAQ:HALO) LogoInvestors sentiment increased to 1.47 in Q2 2019. Its up 0.03, from 1.44 in 2019Q1. It is positive, as 16 investors sold HALO shares while 44 reduced holdings. 28 funds opened positions while 60 raised stakes. 105.70 million shares or 8.25% less from 115.20 million shares in 2019Q1 were reported. Prudential Financial reported 16,716 shares. Daiwa Group Inc invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Gotham Asset Limited Liability Company accumulated 12,970 shares or 0% of the stock. Northwestern Mutual Wealth Com reported 0% stake. Wellington Group Ltd Liability Partnership has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Fred Alger Management reported 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Los Angeles & Equity Rech has invested 0.02% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Jacobs Levy Equity Management Inc has 0.13% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 529,598 shares. The New Jersey-based Nj State Employees Deferred Compensation Plan has invested 0.07% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Paradigm reported 10,000 shares. Sg Americas Securities Ltd Company owns 8,496 shares. Kepos Ltd Partnership reported 0.13% stake. Kennedy Capital Management holds 0.07% or 177,520 shares. Hudson Bay Cap Mngmt LP owns 175,000 shares for 0.07% of their portfolio. First Eagle Inv Management Ltd Company invested in 2.13M shares or 0.09% of the stock.

Senzar Asset Management Llc decreased its stake in Halozyme Therapeutics Inc (HALO) by 6.29% based on its latest 2019Q2 regulatory filing with the SEC. Senzar Asset Management Llc sold 257,074 shares as the company’s stock rose 5.07% . The hedge fund held 3.83M shares of the health care company at the end of 2019Q2, valued at $66.53 million, down from 4.09M at the end of the previous reported quarter. Senzar Asset Management Llc who had been investing in Halozyme Therapeutics Inc for a number of months, seems to be less bullish one the $2.35 billion market cap company. The stock increased 2.62% or $0.41 during the last trading session, reaching $16.05. About 1.38 million shares traded or 83.21% up from the average. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has declined 1.34% since October 12, 2018 and is downtrending. It has underperformed by 1.34% the S&P500.

Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on November, 5. They expect $-0.13 EPS, up 31.58 % or $0.06 from last year’s $-0.19 per share. After $-0.10 actual EPS reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 30.00 % negative EPS growth.

More notable recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: Finance.Yahoo.com which released: “How Many Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Have Insiders Sold, In The Last Year? – Yahoo Finance” on October 02, 2019, also Prnewswire.com with their article: “Halozyme To Participate In 2019 Wells Fargo Healthcare Conference – PRNewswire” published on August 26, 2019, Seekingalpha.com published: “Halozyme on track for key data readout in Q4 – Seeking Alpha” on June 12, 2019. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) were released by: Finance.Yahoo.com and their article: “Why Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) CEO Pay Matters To You – Yahoo Finance” published on September 02, 2019 as well as Prnewswire.com‘s news article titled: “Halozyme Announces argenx Has Selected Second Target Under ENHANZE┬« Technology Collaboration And License Agreement – PRNewswire” with publication date: May 22, 2019.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.